secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001104659-24-115344
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport Q3 revenue flat YoY at $56.7M; services up 9%, product down 14%
------------------------------------------------------------------------

- Net loss attributable to common stockholders: $1.2M ($0.02/share) vs $15.3M loss ($0.31) YoY.
- Life Sciences Services revenue up 9% to $39.3M; gross margin improved to 46%.
- Life Sciences Products revenue down 14% to $17.4M; total gross margin 44.8%.
- Full-year 2024 revenue guidance reaffirmed at $225-235M; management targets positive adjusted EBITDA in 2025.
- Repurchased $175M principal of 2026 convertible notes for $154.5M; cash and short-term investments $272.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465924115344/0001104659-24-115344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465924115344/tm2427809d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-115344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer